We are live on
!
Find out more
HM
HealthCor Management Portfolio holdings
AUM
$109M
1-Year Est. Return
10.64%
This Fund
S&P 500
This Quarter
Est. Return
-23.86%
1 Year Est. Return
+10.64%
3 Year Est. Return
+50.22%
5 Year Est. Return
+140.3%
10 Year Est. Return
–
AUM
$2.34B
AUM Growth
-$463M
(-17%)
Cap. Flow
+$326M
Cap. Flow
% of AUM
13.93%
Top 10 Holdings %
Top 10 Hldgs %
52.09%
Holding
73
New
17
Increased
17
Reduced
10
Closed
27
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Welltower
WELL
|
+$117M |
| 2 |
Encompass Health
EHC
|
+$111M |
| 3 |
AMRN
Amarin Corp
AMRN
|
+$101M |
| 4 |
Haemonetics
HAE
|
+$97.5M |
| 5 |
Bausch Health
BHC
|
+$92.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$140M |
| 2 |
Johnson & Johnson
JNJ
|
+$100M |
| 3 |
HOLX
Hologic
HOLX
|
+$87.5M |
| 4 |
HCA Healthcare
HCA
|
+$65.6M |
| 5 |
XENT
Intersect ENT, Inc
XENT
|
+$63.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 92.58% |
| 2 | Real Estate | 5.41% |
| 3 | Industrials | 0% |
| 4 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Pacira BioSciences
PCRX
$997M
| $29.8M | 1.27% |
887,370
+116,230
| +15% | +$4.83M |
|
|
BLUE
27
DELISTED
bluebird bio
BLUE
| $28.6M | 1.22% |
48,035
-4,494
| -9% | -$4.38M |
|
|
HZNP
28
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $23.5M | 1.01% |
+794,480
| New | +$26.9M |
|
29
Becton Dickinson
BDX
$48.2B
| $23M | 0.98% |
102,500
-118,900
| -54% | -$29.4M |
|
|
HOLX
30
DELISTED
Hologic
HOLX
| $21.9M | 0.94% |
625,240
-1,838,800
| -75% | -$87.5M |
|
|
31
HCA Healthcare
HCA
$89.5B
| $20.6M | 0.88% |
229,730
-506,940
| -69% | -$65.6M |
|
|
BMY.RT
32
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
| $18.3M | 0.78% |
4,825,260
+1,683,419
| +54% | +$5.55M |
|
|
ARNA
33
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $18.3M | 0.78% |
+436,340
| New | +$20M |
|
34
Thermo Fisher Scientific
TMO
$220B
| $17M | 0.73% |
+60,000
| New | +$18.9M |
|
35
State Street SPDR S&P Biotech ETF
XBI
$10.3B
| $15.2M | 0.65% |
+196,850
| New | +$17.4M |
|
36
Biogen
BIIB
$30.7B
| $15.2M | 0.65% |
+48,002
| New | +$14.6M |
|
37
Zymeworks
ZYME
$1.67B
| $14.8M | 0.63% |
+416,700
| New | +$17.1M |
|
38
Agios Pharmaceuticals
AGIO
$1.93B
| $14.5M | 0.62% |
408,844
-288,546
| -41% | -$13.3M |
|
|
ALXN
39
CALL
DELISTED
Alexion Pharmaceuticals
ALXN
| $13.5M | 0.58% |
+150,000
| New | +$14.7M |
|
40
Teva Pharmaceuticals
TEVA
$41.2B
| $13.4M | 0.57% |
+1,492,800
| New | +$15.3M |
|
|
ALXN
41
DELISTED
Alexion Pharmaceuticals
ALXN
| $13.3M | 0.57% |
+148,270
| New | +$14.6M |
|
42
Envista
NVST
$4.52B
| $13.3M | 0.57% |
888,210
-1,957,940
| -69% | -$50.1M |
|
43
Bristol-Myers Squibb
BMY
$132B
| $9.72M | 0.42% |
174,360
-665,640
| -79% | -$40.7M |
|
44
Rocket Pharmaceuticals
RCKT
$394M
| $5.16M | 0.22% |
369,639
-18,721
| -5% | -$371K |
|
|
SRGA
45
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
| $3.69M | 0.16% |
71,955
| – | – |
|
|
PTE
46
DELISTED
PolarityTE, Inc. Common Stock
PTE
| $687K | 0.03% |
25,444
| – | – |
|
47
Axsome Therapeutics
AXSM
$10.9B
| – | – |
-408,617
| Closed | -$42.2M |
|
48
Cigna
CI
$74.6B
| – | – |
-168,730
| Closed | -$34.5M |
|
49
Centene
CNC
$32.5B
| – | – |
-560,900
| Closed | -$35.3M |
|
50
Danaher
DHR
$144B
| – | – |
-371,078
| Closed | -$50.5M |
|
Similar funds
IA
EPC
TCMV
SI
HCWM
PC
RF
AWM
HealthCor Management's Q1 2020 Portfolio in Review
As of Q1 2020, HealthCor Management held 73 positions worth $2.34B, down 17% from $2.8B the previous quarter. Its ten largest holdings account for 52% of the portfolio.
HealthCor Management deployed $326M of net new capital in Q1 2020, opening 17 new positions and adding to 17 existing holdings. Its largest new stake was Welltower: 1,582,360 shares worth $72.4M.
By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 92% a quarter earlier, followed by Real Estate and Industrials.
On the sell side, the largest reduction was Hologic, an estimated $87.5M trimmed.
- HealthCor Management's largest Q1 2020 buy was Welltower: 1,582,360 shares worth $72.4M.
- HealthCor Management added most to Amarin Corp in Q1 2020, an estimated $101M increase.
- HealthCor Management's biggest Q1 2020 reduction was Hologic, cutting an estimated $87.5M.
- HealthCor Management fully exited Regeneron Pharmaceuticals in Q1 2020, selling an estimated $140M.
- HealthCor Management's ten largest holdings make up 52% of its $2.34B portfolio in Q1 2020.
- HealthCor Management opened 17 new positions and closed 27 in Q1 2020.
- HealthCor Management's portfolio value fell 17% quarter-over-quarter to $2.34B.
Based on HealthCor Management's 13F filing for Q1 2020, filed 15 May 2020.